CXCR4 and cancer: The inhibition of CXCR4 using continuous infusion of the small-molecule inhibitor AMD3100 (plerixafor) relieved this suppression, resulting in enhanced T and NK cell infiltration with a concomitant decrease in the recruitment of cancer-associated fibroblasts (CAF) [69].